Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis and HIV news

Show

From To
Low testosterone persists after HCV clearance

Low levels of free testosterone are common among men with chronic hepatitis C infection following SVR and persist after HCV clearance, according to findings from a prospective, longitudinal cohort study.

Published
12 February 2019
From
Healio
Hepatitis C Fight Hinges on Prisons

Lawsuits across the country are seeking better but more expensive care for inmates with the infectious disease, who can spread it upon their release.

Published
05 February 2019
From
U.S. News & World Report
England: Countdown to hep C eradication

NHS England’s target date to eliminate hepatitis C is now just six years away. DDN hears what progress has been made, and what’s left to achieve, at the LJWG on Substance Use and Hepatitis C annual conference.

Published
05 February 2019
From
Drink & Drug News
UK court dismisses AbbVie's legal challenge against the NHS

The High Court has dismissed a legal challenge by US pharmaceutical firm AbbVie against the National Health Service (NHS) England's procurement deal for drugs to treat and cure hepatitis C. The decision means that the plan to eliminate the virus in England remains on track.

Published
25 January 2019
From
The Lancet (free registration required)
Needle and syringe programs cost-effectively prevent hepatitis C transmission

Providing clean injecting equipment through needle and syringe programs is a highly cost-effective way of preventing hepatitis C (HCV) transmission among people who inject drugs and could save millions of pounds in infection treatment costs in the UK, according to research led by the University of Bristol and London School of Hygiene & Tropical Medicine.

Published
24 January 2019
From
Eurekalert Medicine & Health
NHS England’s plan to eliminate Hepatitis C decisively backed by High Court

NHS England’s plan to eliminate Hepatitis C in England by 2025 is on track after all aspects of a High Court challenge by pharmaceutical company AbbVie were dismissed. The NHS’s single largest medicines procurement, a deal worth almost £1 billion over five years, was launched in April last year but contract start dates had to be delayed by six months after legal action by AbbVie.

Published
18 January 2019
From
NHS England
Hepatitis C Prevalent in Less Than 1% of US Population

Epidemiologists found a 0.93% overall prevalence of hepatitis C virus (HCV) infection cases in the US while using a novel assessment method in a new study. The report, which included undiagnosed cases among its prevalence rates, found that approximately half of the cases occurred in just 9 states, including 5 in Appalachia.

Published
18 January 2019
From
MD Magazine
Undiagnosed HBV, HCV, HIV prevalent in newly diagnosed cancer cases

Researchers discovered a substantial proportion of patients with newly diagnosed cancer and concurrent hepatitis C or hepatitis B were unaware of their viral infection and many had no identifiable risk factors, according to a recently published study.

Published
18 January 2019
From
Healio
Egypt proposes plan to treat African Hepatitis C patients

Minister of Health Hala Zayed unveiled an Egyptian initiative to treat African people from Hepatitis C, starting with the Nile Basin countries who have an estimated 3.7 million hepatitis C patients, representing 30 percent of the total number of infected people in Africa.

Published
16 January 2019
From
Egypttoday
Temporary Decline in CD4 T-Cell Count After Hepatitis C Infection in PLWHIV

When hepatitis C (HCV) is acquired in patients with HIV infection, CD4 T-cell counts temporarily decline after HCV seroconversion, regardless of the duration of HIV or whether the patient is on combination antiretroviral therapy (cART), according to study findings published in AIDS.

Published
09 January 2019
From
Infectious Disease Advisor

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.